白细胞介素 (IL)-17 与 IL-23 抑制剂：皮肤科诊所中治疗中重度斑块状银屑病和轻度银屑病关节炎患者，哪种药物更好？

Interleukin (IL)-17 Versus IL-23 Inhibitors: Which Is Better to Treat Patients With Moderate-to-Severe Psoriasis and Mild Psoriatic Arthritis in Dermatology Clinics?

机构信息

R. Agüero, MD, MSc, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

M.J. Woodbury, BS, Harvard Medical School, Boston, Massachusetts, USA.

出版信息

J Rheumatol. 2023 Nov;50(Suppl 2):11-13. doi: 10.3899/jrheum.2023-0511. Epub 2023 Jul 7.

DOI:10.3899/jrheum.2023-0511

PMID:37419622

Abstract

Interleukin (IL)-17 and IL-23 inhibitors are both approved for the treatment of moderate-to-severe plaque psoriasis (PsO), as well as psoriatic arthritis (PsA). In the absence of head-to-head studies, it is not clear which agent is better suited to treat patients with moderate-to-severe PsO and mild PsA. During the 2022 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) conference, Dr. April Armstrong and Dr. Joseph Merola debated which of these 2 biologic classes should be used in this patient population. Armstrong argued in favor of IL-17 inhibition, whereas Merola presented reasons for IL-23 inhibition. An overview of their main arguments is described in this manuscript.

摘要

白细胞介素（IL）-17 和 IL-23 抑制剂均获批用于治疗中重度斑块状银屑病（PsO）和银屑病关节炎（PsA）。由于缺乏头对头研究，尚不清楚哪种药物更适合治疗中重度 PsO 和轻度 PsA 的患者。在 2022 年银屑病和银屑病关节炎研究和评估组织（GRAPPA）会议上，April Armstrong 博士和 Joseph Merola 博士就这两种生物制剂类别应在该患者人群中使用哪一种进行了辩论。Armstrong 博士支持使用 IL-17 抑制剂，而 Merola 博士则提出了使用 IL-23 抑制剂的理由。本文概述了他们的主要论点。